{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:11:21Z","timestamp":1793146281196,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Education Department of Jiangsu Province","award":["19KJB320020"],"award-info":[{"award-number":["19KJB320020"]}]},{"name":"Education Department of Suzhou Government","award":["SYS2020107"],"award-info":[{"award-number":["SYS2020107"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer is the most lethal gynecologic malignancy worldwide. Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), is becoming widely used in ovarian cancer treatment. The overall survival of ovarian cancer has not been significantly changed over the past decades and ovarian cancer has become increasingly resistant to the Olaparib. Ubiquitin-conjugating enzyme E2S (UBE2S) has been proved to promote malignant behaviors in many cancers. However, the function of UBE2S in the development and Olaparib resistance of ovarian cancer are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this study, we detected the expression of UBE2S in normal fallopian tube (FT) and HGSOC tissues. A2780 and SKOV3 cells were stably transfected with PCMV-UBE2S, PCMV-UBE2S-C95S, UBE2S shRNAs, and negative controls. The CCK8 assay and clonogenic assay were conducted to analyze ovarian cancer proliferation and Olaparib resistance. The transwell assay was performed to determine the migration and invasion of ovarian cancer cells. The relative protein levels of the Wnt\/\u03b2-catenin signaling pathway were tested using western blot. The ovarian cancer cells were treated with XAV-939 to investigate the role of Wnt\/\u03b2-catenin signaling pathway in Olaparib resistance. Moreover, we repeated some above procedures in the xenograft model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results demonstrated that UBE2S was highly upregulated in HGSOC and that high UBE2S expression was correlated with poor outcomes in HGSOC. UBE2S promoted ovarian cancer proliferation and drived the migration and invasion of ovarian cancer cells. UBE2S activated the Wnt\/\u03b2-catenin signaling pathway in ovarian cancer resulting in Olaparib resistance in vitro and in vivo. Furthermore, UBE2S enhanced the proliferation and Olaparib resistance of ovarian cancer in its enzymatic activity dependent manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data suggest a possible molecular mechanism of proliferation and metastasis of ovarian cancer and highlight the potential role of UBE2S as a therapeutic target in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-021-00877-y","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T04:09:53Z","timestamp":1631851793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt\/\u03b2-catenin signaling pathway"],"prefix":"10.1186","volume":"14","author":[{"given":"Wenjing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","unstructured":"Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20040952.","DOI":"10.3390\/ijms20040952"},{"key":"877_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"PM Webb","year":"2017","unstructured":"Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3\u201314. https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.08.006.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"877_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396. https:\/\/doi.org\/10.3322\/caac.21456.","journal-title":"CA Cancer J Clin"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.7150\/ijms.40243","volume":"17","author":"Y Qin","year":"2020","unstructured":"Qin Y, Du J, Fan C. Ube2S regulates Wnt\/beta-catenin signaling and promotes the progression of non-small cell lung cancer. Int J Med Sci. 2020;17:274\u20139. https:\/\/doi.org\/10.7150\/ijms.40243.","journal-title":"Int J Med Sci"},{"key":"877_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.biocel.2019.01.014","volume":"109","author":"M Lin","year":"2019","unstructured":"Lin M, et al. UBE2S mediates tumor progression via SOX6\/beta-catenin signaling in endometrial cancer. Int J Biochem Cell Biol. 2019;109:17\u201322. https:\/\/doi.org\/10.1016\/j.biocel.2019.01.014.","journal-title":"Int J Biochem Cell Biol"},{"key":"877_CR6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbrc.2018.06.093","volume":"503","author":"Y-H Pan","year":"2018","unstructured":"Pan Y-H, et al. UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma. Biochem Biophys Res Commun. 2018;503:895\u2013902. https:\/\/doi.org\/10.1016\/j.bbrc.2018.06.093.","journal-title":"Biochem Biophys Res Commun"},{"key":"877_CR7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1073\/pnas.0912802107","volume":"107","author":"T Wu","year":"2010","unstructured":"Wu T, et al. UBE2S drives elongation of K11-linked ubiquitin chains by the anaphase-promoting complex. Proc Natl Acad Sci U S A. 2010;107:1355\u201360. https:\/\/doi.org\/10.1073\/pnas.0912802107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"877_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","volume":"10","author":"SG Pai","year":"2017","unstructured":"Pai SG, et al. Wnt\/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10:101. https:\/\/doi.org\/10.1186\/s13045-017-0471-6.","journal-title":"J Hematol Oncol"},{"key":"877_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985\u201399. https:\/\/doi.org\/10.1016\/j.cell.2017.05.016.","journal-title":"Cell"},{"key":"877_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ygyno.2013.09.034","volume":"131","author":"RC Arend","year":"2013","unstructured":"Arend RC, Londono-Joshi AI, Straughn JM, Buchsbaum DJ. The Wnt\/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013;131:772\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2013.09.034.","journal-title":"Gynecol Oncol"},{"key":"877_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13048-019-0596-z","volume":"12","author":"VHL Nguyen","year":"2019","unstructured":"Nguyen VHL, Hough R, Bernaudo S, Peng C. Wnt\/\u03b2-catenin signalling in ovarian cancer: insights into its hyperactivation and function in tumorigenesis. J Ovarian Res. 2019;12:122. https:\/\/doi.org\/10.1186\/s13048-019-0596-z.","journal-title":"J Ovarian Res"},{"key":"877_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.gene.2018.11.098","volume":"689","author":"Q Liu","year":"2019","unstructured":"Liu Q, et al. The role of R-spondin 1 through activating Wnt\/\u03b2-catenin in the growth, survival and migration of ovarian cancer cells. Gene. 2019;689:124\u201330. https:\/\/doi.org\/10.1016\/j.gene.2018.11.098.","journal-title":"Gene"},{"key":"877_CR13","doi-asserted-by":"publisher","unstructured":"Teeuwssen M, Fodde R. Wnt signaling in ovarian cancer stemness, EMT, and therapy resistance. J Clin Med. 2019;8. https:\/\/doi.org\/10.3390\/jcm8101658.","DOI":"10.3390\/jcm8101658"},{"key":"877_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41419-018-0451-y","volume":"9","author":"Z Li","year":"2018","unstructured":"Li Z, et al. Ube2s stabilizes beta-catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development. Cell Death Dis. 2018;9:456. https:\/\/doi.org\/10.1038\/s41419-018-0451-y.","journal-title":"Cell Death Dis"},{"key":"877_CR15","doi-asserted-by":"publisher","first-page":"9767","DOI":"10.2147\/ott.S228522","volume":"12","author":"L Wang","year":"2019","unstructured":"Wang L, et al. Oncogenic activities of UBE2S mediated by VHL\/HIF-1\u03b1\/STAT3 signal via the ubiquitin-proteasome system in PDAC. Onco Targets Ther. 2019;12:9767\u201381. https:\/\/doi.org\/10.2147\/ott.S228522.","journal-title":"Onco Targets Ther"},{"key":"877_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.5483\/BMBRep.2018.51.12.138","volume":"51","author":"Z Liu","year":"2018","unstructured":"Liu Z, Xu L. UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. BMB Rep. 2018;51:642\u20137. https:\/\/doi.org\/10.5483\/BMBRep.2018.51.12.138.","journal-title":"BMB Rep"},{"key":"877_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41419-018-0451-y","volume":"9","author":"Z Li","year":"2018","unstructured":"Li Z, et al. Ube2s stabilizes \u03b2-catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development. Cell Death Dis. 2018;9:456. https:\/\/doi.org\/10.1038\/s41419-018-0451-y.","journal-title":"Cell Death Dis"},{"key":"877_CR18","doi-asserted-by":"publisher","unstructured":"Wang P, et al. Comprehensive investigation into the role of ubiquitin-conjugating enzyme E2S in melanoma development. J Invest Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jid.2020.05.113.","DOI":"10.1016\/j.jid.2020.05.113"},{"key":"877_CR19","doi-asserted-by":"publisher","first-page":"640910","DOI":"10.3389\/fonc.2021.640910","volume":"11","author":"L Hu","year":"2021","unstructured":"Hu L, et al. Molecular and clinical characterization of UBE2S in glioma as a biomarker for poor prognosis and resistance to chemo-radiotherapy. Front Oncol. 2021;11:640910. https:\/\/doi.org\/10.3389\/fonc.2021.640910.","journal-title":"Front Oncol"},{"key":"877_CR20","doi-asserted-by":"publisher","first-page":"9767","DOI":"10.2147\/OTT.S228522","volume":"12","author":"L Wang","year":"2019","unstructured":"Wang L, et al. Oncogenic activities of UBE2S mediated by VHL\/HIF-1alpha\/STAT3 signal via the ubiquitin-proteasome system in PDAC. Onco Targets Ther. 2019;12:9767\u201381. https:\/\/doi.org\/10.2147\/OTT.S228522.","journal-title":"Onco Targets Ther"},{"key":"877_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","volume":"73","author":"E Franzese","year":"2019","unstructured":"Franzese E, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2019;73:1\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2018.12.002.","journal-title":"Cancer Treat Rev"},{"key":"877_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34:360\u201394. https:\/\/doi.org\/10.1101\/gad.334516.119.","journal-title":"Genes Dev"},{"key":"877_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-pathol-020117-044010","volume":"13","author":"JO Russell","year":"2018","unstructured":"Russell JO, Monga SP. Wnt\/\u03b2-catenin signaling in liver development, homeostasis, and pathobiology. Annu Rev Pathol. 2018;13:351\u201378. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-044010.","journal-title":"Annu Rev Pathol"},{"key":"877_CR24","doi-asserted-by":"publisher","unstructured":"Ram Makena M, et al. Wnt\/\u03b2-Catenin signaling: the culprit in pancreatic carcinogenesis and therapeutic resistance. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20174242.","DOI":"10.3390\/ijms20174242"},{"key":"877_CR25","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/ncb1983","volume":"11","author":"MJ Garnett","year":"2009","unstructured":"Garnett MJ, et al. UBE2S elongates ubiquitin chains on APC\/C substrates to promote mitotic exit. Nat Cell Biol. 2009;11:1363\u20139. https:\/\/doi.org\/10.1038\/ncb1983.","journal-title":"Nat Cell Biol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00877-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-021-00877-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00877-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T04:13:01Z","timestamp":1631851981000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00877-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00877-y","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"8 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the experiments were approved by the Ethics Committee of the First Affiliated Hospital of Soochow University, and written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}